Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SY-9453 in Advanced Solid Tumors
NCT07469982Phase 1Recruiting
- Sponsor
- Shouyao Holdings
- Start
- Mar 2026
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SY-9453 in solid tumor, sponsored by Shouyao Holdings. Primary endpoints: Incidence of adverse events at 3 years, Incidence of dose limiting toxicities at 35 days and 3 more. Started Mar 2026; status: recruiting.
02
Drugs
SY-9453
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07469982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07469982.